Tevogen Inc. TVGN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2022 · data as of November 13, 2026
Tevogen Inc. (TVGN) is a healthcare company listed in the US with a market value of about $407M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
About Tevogen
Tevogen is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2022. It was profitable in 1 of the last 4 years in our data.
Score: 0.2 / 5
Checks passed
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net income | -$26M | -$14M | -$60M | $4M |
| Free cash flow | -$12M | — | -$8M | — |
| EPS (diluted) | $-0.40 | $-0.17 | $-6.10 | — |
| Net margin | — | — | — | — |
| ROIC | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Tevogen pay a dividend?
Not currently.
Is Tevogen a good stock to buy?
We do not give buy or sell advice. Tevogen scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.